Artios Pharma Ltd raises US-$153m Series C financing
Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
AXA IM Alts raises 1.9bn European Life Sciences Fund
/in News/by Thomas GabrielczykAXA IM Alts has raised 1.9bn of equity to accelerate investments into the Life Sciences sector.
Synaffix inks $246m deal with ProfoundBio
/in News/by Thomas GabrielczykSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Stada und Calliditas Therapeutics in 97,5 Mio. Euro-Deal
/in News/by Thomas GabrielczykDie Stada Arzneimittel AG zahlt im Rahmen eines EU-Marketingabkommens für Nefecon zur Behandlung der IgA-Nephropathie vorab 20 Mio. Euro an die Calliditas Therapeutics AB.
Nanosyrinx raises £6.2m to validate drug delivery platform
/in News/by Thomas GabrielczykCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
Unilever licences Arzeda Inc.s enzyme technology
/in News/by Thomas GabrielczykAs part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Bio-Me raises NOK10m
/in News/by Thomas GabrielczykOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Novalis Biotech closes biotech fund at 25m
/in News/by Thomas GabrielczykEarly-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at 25m to drive growth of translational medicine start-ups.
Cellink AB to take-over Discover Echo Inc
/in News/by Thomas GabrielczykSwedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Rheincell set to be acquired by Catalent
/in News/by Thomas GabrielczykMajor CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.